Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Stock Quote Today & Recent News Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:VM)

Voyageur Pharmaceuticals announces $1M raise for contrast drug testing

Coreena Robertson October 29, 2024

Voyageur Announces Proposed Private Placement

Newsfile October 17, 2024

One of the best Venture pharma stocks has grown even stronger

Jonathon Brown October 3, 2024

Voyageur Pharmaceuticals Grants Stock Options

Newsfile September 25, 2024

Voyageur Pharmaceuticals Strengthens Leadership Team with Strategic Appointment of Dr. Ibrahim Hashmi as VP of Business Development

TheNewsWire September 24, 2024

Voyageur Pharmaceuticals Appoints Dr. Iryna Saranchova as Chief Science Officer, Enhancing the Company's Research and Innovation Leadership

TheNewsWire September 17, 2024
View More News ››

Opinion & Analysis (TSXV:VM)

Progress for radiology drugs and medical imaging company

Shoran Devi June 12, 2023

Health Canada Approvals Set Stage for Revenue Generation

Dave Jackson February 25, 2021

From the Earth to the Bottle

Dave Jackson January 21, 2020

VIDEO: High Grade Barite Producer

BTV-Business Television May 18, 2017
View More Opinion ››

Bullboard Posts (TSXV:VM)

RE:was VM being spoofed

https://www.ciro.ca/news-room/publications/guidance-certain-manipulative-and-deceptive-trading-practices As for myself I have often...
postie1 - 6 days ago

was VM being spoofed

Read an interesting post about a lawsuit by a company that claims it is was  the victim of a spoofing scheme over 4 yrs.  With...
postie1 - 7 days ago

RE:RE:Bracco News Release

soooo...why are you still here?
JrOGInvestor - 8 days ago

RE:Bracco News Release

Yeah it's all good.  A shame though they can't even partially close a PP near all time lows.  No money = no more VM....
oldtrouf - 8 days ago

Bracco News Release

A very interesting read, also noticed they don't appear to do a lot of press releases given there's two articles on that page...
JrOGInvestor - 9 days ago

Bracco news

  BRACCO TRIPLES PRODUCTION OF ITS INNOVATIVE CONTRAST AGENT...
lscfa - 9 days ago
View more Bullboard ››

Connect with V.VM

follow v.vm on


PRODUCTS PIPELINE CARBON DRUG PROJECT WHITE PAPER CASE STUDIES MANAGEMENT PRESENTATION

Voyageur Pharmaceuticals Deck 2024

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1